Enanta Pharmaceuticals Major Shareholder Sells $287,697 in Stock (ENTA)
Enanta Pharmaceuticals (NASDAQ:ENTA) major shareholder Saints Capital Granite, L.P. sold 12,300 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $23.39, for a total value of $287,697.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded down 3.96% during mid-day trading on Friday, hitting $21.84. 163,819 shares of the company’s stock traded hands. Enanta Pharmaceuticals has a 52-week low of $14.31 and a 52-week high of $26.39. The stock’s 50-day moving average is $20.56 and its 200-day moving average is $19.31. The company’s market cap is $391.2 million.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.23) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.34) by $0.11. The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $0.73 million. On average, analysts predict that Enanta Pharmaceuticals will post $-1.26 earnings per share for the current fiscal year.
Separately, analysts at Zacks upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday. They now have a $25.40 price target on the stock. Five investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average target price of $27.20.
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.